LLY

1,005.32

+0.99%↑

JNJ

244.16

+0.94%↑

ABBV

227.42

+1.18%↑

NVS

162.4

+1.23%↑

AZN

197.55

+2.64%↑

LLY

1,005.32

+0.99%↑

JNJ

244.16

+0.94%↑

ABBV

227.42

+1.18%↑

NVS

162.4

+1.23%↑

AZN

197.55

+2.64%↑

LLY

1,005.32

+0.99%↑

JNJ

244.16

+0.94%↑

ABBV

227.42

+1.18%↑

NVS

162.4

+1.23%↑

AZN

197.55

+2.64%↑

LLY

1,005.32

+0.99%↑

JNJ

244.16

+0.94%↑

ABBV

227.42

+1.18%↑

NVS

162.4

+1.23%↑

AZN

197.55

+2.64%↑

LLY

1,005.32

+0.99%↑

JNJ

244.16

+0.94%↑

ABBV

227.42

+1.18%↑

NVS

162.4

+1.23%↑

AZN

197.55

+2.64%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

38.12 -0.13

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

37.67

Max

38.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	7.3M -123M
Pardavimai	3.7M 3.9M
Pelnas, tenkantis vienai akcijai	-1.29
Pelno marža	-3,161.261
Darbuotojai	437
EBITDA	20M -122M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+130.19% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-319M 4.2B
Ankstesnė atidarymo kaina	38.25
Ankstesnė uždarymo kaina	38.12

Naujienos nuotaikos

By Acuity

21%

79%

30 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-09 18:13; UTC

Įsigijimai, susijungimai, perėmimai

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

2026-03-09 17:20; UTC

Svarbiausios naujienos

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

2026-03-09 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

2026-03-10 00:00; UTC

Svarbiausios naujienos

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

2026-03-09 23:52; UTC

Rinkos pokalbiai

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

2026-03-09 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

2026-03-09 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-09 23:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Correction to Crude Prices Market Talk on March 9

2026-03-09 23:42; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

2026-03-09 23:08; UTC

Svarbiausios naujienos

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

2026-03-09 23:07; UTC

Svarbiausios naujienos

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

2026-03-09 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue Now Fully Owns Peru's Canariaco Copper Project

2026-03-09 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue Completes Acquisition of Remaining Alta Copper Shares

2026-03-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-09 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-09 20:47; UTC

Svarbiausios naujienos

The 24 Hours When Oil Markets Went Wild -- WSJ

2026-03-09 20:33; UTC

Svarbiausios naujienos

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

2026-03-09 20:14; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

2026-03-09 19:33; UTC

Svarbiausios naujienos

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

2026-03-09 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

2026-03-09 19:14; UTC

Rinkos pokalbiai

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

2026-03-09 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026-03-09 18:23; UTC

Rinkos pokalbiai

Svarbiausios naujienos

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

2026-03-09 17:58; UTC

Įsigijimai, susijungimai, perėmimai

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

2026-03-09 17:57; UTC

Įsigijimai, susijungimai, perėmimai

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

2026-03-09 17:41; UTC

Svarbiausios naujienos

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

2026-03-09 17:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

2026-03-09 17:08; UTC

Rinkos pokalbiai

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

2026-03-09 17:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-09 17:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

130.19% į viršų

12 mėnesių prognozė

Vidutinis 88 USD 130.19%

Aukščiausias 97 USD

Žemiausias 67 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

30 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.